Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00023790 | Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin | terminated | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 24, 2011 | clinicaltrials |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | terminated | Phase 1 | 3 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00112619 | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors | terminated | Phase 1 | 19 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00460460 | Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies | terminated | Phase 1 | 75 | AstraZenecaINDUSTRY | 2 | Jan 25, 2011 | clinicaltrials |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | terminated | Phase 1 | 20 | BiogenINDUSTRY | 1 | Jan 7, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00003567 | Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 8 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00471367 | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00955292 | Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 12 | Cylene PharmaceuticalsINDUSTRY | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00147485 | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | terminated | Phase 1 | — | ExelixisINDUSTRY | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00363610 | A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma | terminated | Phase 1 | 19 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 24 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00100347 | Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors | terminated | Phase 1 | 45 | PRAECIS Pharmaceuticals Inc.INDUSTRY | 1 | Jul 25, 2007 | clinicaltrials |
| NCT00105313 | Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia | terminated | Phase 1 | 80 | MedImmune LLCINDUSTRY | 1 | Jun 14, 2007 | clinicaltrials |
| NCT00023166 | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas | terminated | Phase 1 | — | Enzon Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2011source: clinicaltrials